Ayako Kamiunten

766 total citations
21 papers, 188 citations indexed

About

Ayako Kamiunten is a scholar working on Immunology, Molecular Biology and Genetics. According to data from OpenAlex, Ayako Kamiunten has authored 21 papers receiving a total of 188 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 8 papers in Molecular Biology and 8 papers in Genetics. Recurrent topics in Ayako Kamiunten's work include T-cell and Retrovirus Studies (8 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers) and Vector-Borne Animal Diseases (6 papers). Ayako Kamiunten is often cited by papers focused on T-cell and Retrovirus Studies (8 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers) and Vector-Borne Animal Diseases (6 papers). Ayako Kamiunten collaborates with scholars based in Japan. Ayako Kamiunten's co-authors include Takuro Kameda, Kazuya Shimoda, Kotaro Shide, Yoko Kubuki, Masaaki Sekine, Tomonori Hidaka, Satoru Hasuike, Kenji Nagata, Hisayoshi Iwakiri and Keiichi Akizuki and has published in prestigious journals such as Blood, Leukemia and BMC Cancer.

In The Last Decade

Ayako Kamiunten

19 papers receiving 186 citations

Peers

Countries citing papers authored by Ayako Kamiunten

Since Specialization

Citations

This map shows the geographic impact of Ayako Kamiunten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ayako Kamiunten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ayako Kamiunten more than expected).

Fields of papers citing papers by Ayako Kamiunten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ayako Kamiunten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ayako Kamiunten. The network helps show where Ayako Kamiunten may publish in the future.

Co-authorship network of co-authors of Ayako Kamiunten

This figure shows the co-authorship network connecting the top 25 collaborators of Ayako Kamiunten. A scholar is included among the top collaborators of Ayako Kamiunten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ayako Kamiunten. Ayako Kamiunten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical Outcomes of Tucidinostat Therapy for Relapsed/Refractory Adult T-Cell Leukemia-Lymphoma (ATL) in Clinical Practice 2023 ·Blood ·Ayako Kamiunten	1
2	Preclinical Translational Research Suggests a Clinical Trial Strategy for a Novel MALT1 Inhibitor ONO-7018/CTX-177 Against Malignant Lymphomas 2022 ·Blood ·Daisuke Morishita, Akio Mizutani, (unknown), Yasuyoshi Arikawa, (unknown), Takuro Kameda, Ayako Kamiunten, (unknown), (unknown), Yotaro Ochi, Kotaro Shide, Koji Izutsu, Yosuke Minami, Kazuya Shimoda, Seishi Ogawa	1
3	Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms 2020 ·Blood ·Kotaro Shide, Takuro Kameda, Ayako Kamiunten, (unknown), Yuki Tahira, Takako Yokomizo‐Nakano, Sho Kubota, Masaya Ono, Kazuhiko Ikeda, Masaaki Sekine, Keiichi Akizuki, Kenichi Nakamura, Tomonori Hidaka, Yoko Kubuki, Hisayoshi Iwakiri, Satoru Hasuike, Kenji Nagata, Goro Sashida, Kazuya Shimoda	10
4	CARD11 Mutation Induces Oligoclonal Expansion of T-Cells, and Accelerates ATL Development in Combination with HBZ 2020 ·Blood ·Takuro Kameda, Kotaro Shide, Ayako Kamiunten, Yuki Tahira, Masaaki Sekine, Keiichi Akizuki, Tomonori Hidaka, Yoko Kubuki, (unknown), Daisuke Morishita, Kazuya Shimoda	2
5	TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia 2020 ·BMC Cancer ·Keiichi Akizuki, Masaaki Sekine, Yasunori Kogure, Takuro Kameda, Kotaro Shide, Junji Koya, Ayako Kamiunten, Yoko Kubuki, Yuki Tahira, Tomonori Hidaka, (unknown), Hiroyuki Tanaka, Yuichiro Sato, Hiroaki Kataoka, Keisuke Kataoka, Kazuya Shimoda	17
6	Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice 2020 ·Leukemia ·(unknown), Kotaro Shide, Takuro Kameda, Ayako Kamiunten, Yuki Tahira, Masaaki Sekine, Keiichi Akizuki, Kenichi Nakamura, Hisayoshi Iwakiri, (unknown), Tomonori Hidaka, Yoko Kubuki, Shojiro Yamamoto, Satoru Hasuike, Akira Sawaguchi, Kenji Nagata, Kazuya Shimoda	29
7	Dissecting Multicellular Ecosystems of HTLV-1 Infection and ATL By Multi-Omics Single Cell Analysis 2020 ·Blood ·(unknown), Yuki Saito, Takuro Kameda, Yasunori Kogure, Marni B. McClure, Sumito Shingaki, Mariko Tabata, Ayako Kamiunten, Kotaro Shide, Kazuya Shimoda, (unknown)	0
8	Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/Refractory Lymphomas 2020 ·Blood ·Daisuke Morishita, Akio Mizutani, (unknown), Yasuyoshi Arikawa, Takuro Kameda, Ayako Kamiunten, Keisuke Kataoka, Akinori Yoda, Yotaro Ochi, Kotaro Shide, Koji Izutsu, Yosuke Minami, Kazuya Shimoda, Hiroshi Miyake, Seishi Ogawa	2
9	Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan 2020 ·Journal of Clinical Medicine ·Keiichi Akizuki, Hitoshi Matsuoka, (unknown), Ayako Kamiunten, Masaaki Sekine, Kotaro Shide, Takuro Kameda, Noriaki Kawano, (unknown), Masanori Takeuchi, Hiroshi Kawano, Seiichi Sato, (unknown), Yuki Tahira, Haruko Shimoda, Tomonori Hidaka, Kiyoshi Yamashita, Yoko Kubuki, Kazuya Shimoda	9
10	Monocyte-derived fibrocytes elimination had little contribution on liver fibrosis 2019 ·Hepatobiliary & pancreatic diseases international ·(unknown), Kotaro Shide, (unknown), (unknown), (unknown), Ayako Kamiunten, Takuro Kameda, Kenichi Nakamura, Tadashi Miike, Kazunori Kusumoto, Hisayoshi Iwakiri, Satoru Hasuike, Kenji Nagata, Akira Sawaguchi, Kazuya Shimoda	3
11	[Myeloproliferative neoplasms: revisions in the 2016 WHO criteria]. 2019 ·PubMed ·Tomonori Hidaka, Ayako Kamiunten, Kazuya Shimoda	0
12	Outcome of allogeneic hematopoietic cell transplantation in patients with adult T‐cell leukemia 2018 ·Hematological Oncology ·Ayako Kamiunten, Masaaki Sekine, Takuro Kameda, Keiichi Akizuki, Yuki Tahira, Kotaro Shide, Haruko Shimoda, Koji Kato, Tomonori Hidaka, Yoko Kubuki, Kazuya Shimoda	4
13	Haploinsufficiency of CALR Confers Hematopoietic Stem Cells (HSCs) with a Clonal Advantage over Wild-Type Cells, and, in Setting of Myeloproliferative Neoplasms, Compensates for the Functions of HSCs Impaired By the Calr Mutation 2018 ·Blood ·Kotaro Shide, Takuro Kameda, Ayako Kamiunten, Masaaki Sekine, (unknown), Takako Yokomizo‐Nakano, Keiichi Akizuki, Yuki Tahira, Yoko Kubuki, Tomonori Hidaka, Goro Sashida, Kazuya Shimoda	2
14	Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm 2017 ·Anticancer Research ·(unknown), Kotaro Shide, Takuro Kameda, Masaaki Sekine, Ayako Kamiunten, Tomonori Hidaka, Yoko Kubuki, Haruko Shimoda, (unknown), Tadashi Miike, Hisayoshi Iwakiri, Yoshihiro Tahara, (unknown), Shojiro Yamamoto, Satoru Hasuike, Kenji Nagata, Kazuya Shimoda	1
15	Effects of mogamulizumab in adult T‐cell leukemia/lymphoma in clinical practice 2017 ·European Journal Of Haematology ·Masaaki Sekine, Yoko Kubuki, Takuro Kameda, Masanori Takeuchi, (unknown), Noriaki Kawano, (unknown), Seiichi Sato, (unknown), Hiroshi Kawano, Ayako Kamiunten, Keiichi Akizuki, Yuki Tahira, Haruko Shimoda, Kotaro Shide, Tomonori Hidaka, Akira Kitanaka, Kiyoshi Yamashita, Hitoshi Matsuoka, Kazuya Shimoda	17
16	Mogamulizumab for ATLL in Clinical Practice 2016 ·Blood ·Masaaki Sekine, Masaki Takeuchi, (unknown), (unknown), Seiichi Sato, Kiyoshi Yamashita, (unknown), Keiichi Akizuki, Ayako Kamiunten, Takuro Kameda, Kotaro Shide, Tomonori Hidaka, Yoko Kubuki, Akira Kitanaka, Kazuya Shimoda	1
17	Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms 2015 ·Genomics Data ·Takuro Kameda, Kotaro Shide, (unknown), Ayako Kamiunten, Masaaki Sekine, Tomonori Hidaka, Yoko Kubuki, Goro Sashida, Kazumasa Aoyama, Makoto Yoshimitsu, (unknown), Tadashi Miike, Hisayoshi Iwakiri, Yoshihiro Tahara, Shojiro Yamamoto, Satoru Hasuike, Kenji Nagata, Atsushi Iwama, Akira Kitanaka, Kazuya Shimoda	3
18	TET2 Mutation in Adult T-Cell Leukemia/Lymphoma 2015 ·Journal of Clinical and Experimental Hematopathology ·Kazuya Shimoda, Kotaro Shide, Takuro Kameda, Tomonori Hidaka, Yoko Kubuki, Ayako Kamiunten, Masaaki Sekine, Keiichi Akizuki, Haruko Shimoda, (unknown), Kenichi Nakamura, (unknown), Tadashi Miike, Hisayoshi Iwakiri, Yoshihiro Tahara, (unknown), Shojiro Yamamoto, Satoru Hasuike, Kenji Nagata, Akira Kitanaka	16
19	Nasopharyngeal Carcinoma with Bone Marrow Metastasis: Positive Response to Weekly Paclitaxel Chemotherapy 2015 ·Internal Medicine ·(unknown), Akira Kitanaka, Yoko Kubuki, Tomonori Hidaka, Kotaro Shide, Takuro Kameda, Masaaki Sekine, Ayako Kamiunten, (unknown), (unknown), (unknown), Kazuya Shimoda	5
20	TET2 is essential for survival and hematopoietic stem cell homeostasis 2012 ·Leukemia ·Kotaro Shide, Takuro Kameda, Haruko Shimoda, (unknown), (unknown), Ayako Kamiunten, Masaaki Sekine, Tomonori Hidaka, (unknown), Yoko Kubuki, Shojiro Yamamoto, Tadashi Miike, Hisayoshi Iwakiri, Satoru Hasuike, Kenji Nagata, Kousuke Marutsuka, Atsushi Iwama, Tadashi Matsuda, Akira Kitanaka, Kazuya Shimoda	64

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact